» Articles » PMID: 25709093

RNA Degradation in Antiviral Immunity and Autoimmunity

Overview
Journal Trends Immunol
Date 2015 Feb 25
PMID 25709093
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Post-transcriptional control determines the fate of cellular RNA molecules. Nonsense-mediated decay (NMD) provides quality control of mRNA, targeting faulty cellular transcripts for degradation by multiple nucleases including the RNA exosome. Recent findings have revealed a role for NMD in targeting viral RNA molecules, thereby restricting virus infection. Interestingly, NMD is also linked to immune responses at another level: mutations affecting the NMD or RNA exosome machineries cause chronic activation of defence programmes, resulting in autoimmune phenotypes. Here we place these observations in the context of other links between innate antiviral immunity and type I interferon mediated disease and examine two models: one in which expression or function of pathogen sensors is perturbed and one wherein host-derived RNA molecules with a propensity to activate such sensors accumulate.

Citing Articles

Established and Emerging Roles of DEAD/H-Box Helicases in Regulating Infection and Immunity.

Parthun M, Long M, Hemann E Immunol Rev. 2024; 329(1):e13426.

PMID: 39620586 PMC: 11741935. DOI: 10.1111/imr.13426.


Enhancing Cytoplasmic Expression of Exogenous mRNA Through Dynamic Mechanical Stimulation.

Chen J, Patel A, Mir M, Hudock M, Pinezich M, Guenthart B Adv Healthc Mater. 2024; 14(1):e2401918.

PMID: 39440644 PMC: 11695169. DOI: 10.1002/adhm.202401918.


Potential Application of Modified mRNA in Cardiac Regeneration.

Wang A, Chang Y, Chen K, Loh C Cell Transplant. 2024; 33:9636897241248956.

PMID: 38715279 PMC: 11080755. DOI: 10.1177/09636897241248956.


Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.

Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers J Ann Rheum Dis. 2024; 83(7):889-900.

PMID: 38373843 PMC: 11187369. DOI: 10.1136/ard-2023-224795.


CCND2 Modified mRNA Activates Cell Cycle of Cardiomyocytes in Hearts With Myocardial Infarction in Mice and Pigs.

Sun J, Wang L, Matthews R, Walcott G, Lu Y, Wei Y Circ Res. 2023; 133(6):484-504.

PMID: 37565345 PMC: 10529295. DOI: 10.1161/CIRCRESAHA.123.322929.


References
1.
Crow Y, Chase D, Lowenstein Schmidt J, Szynkiewicz M, Forte G, Gornall H . Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015; 167A(2):296-312. PMC: 4382202. DOI: 10.1002/ajmg.a.36887. View

2.
Samuel C . Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology. 2011; 411(2):180-93. PMC: 3057271. DOI: 10.1016/j.virol.2010.12.004. View

3.
Tsuda K, Katagiri F . Comparing signaling mechanisms engaged in pattern-triggered and effector-triggered immunity. Curr Opin Plant Biol. 2010; 13(4):459-65. DOI: 10.1016/j.pbi.2010.04.006. View

4.
Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

5.
Mannion N, Greenwood S, Young R, Cox S, Brindle J, Read D . The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014; 9(4):1482-94. PMC: 4542304. DOI: 10.1016/j.celrep.2014.10.041. View